Brodalumab OverviewBrodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017 it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments. Mechanism of action Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. This me...
Read more Brodalumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brodalumab
Recent Brodalumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 210mg/1.5ml
Other drugs which contain Brodalumab or a similar ingredient: (1 result)
- SILIQ Brodalumab